Enhanced expression of NGFR was shown in melanoma cells with acquired resistance to BRAF inhibition or combined BRAF/MEK inhibition [59,60], but it was also a part of a response to treatment preceding development of resistance to MEK inhibition [61]. Here, MAP2K7 is linked to melanoma.